S. Y. Ablordeppey et al. / Bioorg. Med. Chem. 16 (2008) 7291–7301
7301
8. Sikazwe, D. M. N.; Li, S.; Mardenborough, L.; Cody, V.; Roth, B. L.; Ablordeppey,
S. Y. Bioorg. Med. Chem. Lett. 2004, 14, 5739.
9. Sikazwe, D. M. N.; Li, S.; Lyles-Eggleston, M.; Ablordeppey, S. Y. Bioorg. Med.
Chem. Lett. 2003, 13, 3779.
10. Tacke, R.; Popp, F.; Müller, B.; Theis, B.; Burschka, C.; Hamacher, A.; Kassack, M.
U.; Schepmann, D.; Wünsch, B.; Jurva, U.; Wellner, E. ChemMedChem 2008, 3,
152.
11. (a) McIntyre, R. S.; McCann, S. M.; Kennedy, S. H. Can. J. Psychiatry 2001, 46,
273; (b) Taylor, D. M.; McAskill, R. Acta Psychiatry Scand. 2000, 101, 416; (c)
Wirshing, D. A.; Spellberg, B. J.; Erhart, S. M.; Marder, S. R.; Wirshing, W. C. Biol.
Psychiatry 1998, 44, 778.
12. (a) Seeger, T. F.; Seymour, P. A.; Schmidt, A. W.; Zorn, S. H.; Schulz, D. W.; Lebel,
L. A.; McLean, S.; Guanowsky, V.; Howard, H. R.; Lowe, J. A.; Heym, J. J.
Pharmacol. Exp. Ther. 1995, 275, 101; (b) Schmidt, A. W.; Lebel, L. A.; Howard, H.
R., Jr.; Zorn, S. H. Eur. J. Pharmacol. 2001, 425, 197; (c) McCreary, A. C.; Glennon,
J. C.; Ashby, C. R., Jr.; Meltzer, H. Y.; Li, Z.; Reinders, J. H.; Hesselink, M. B.; Long,
S. K.; Herremans, A. H.; van Stuivenberg, H.; Feenstra, R. W.; Kruse, C. G.
Neuropsychopharmacology 2007, 32, 78.
were dosed by IP injection with 1–23 mL/kg of vehicle (filtered 1%
lactic acid), haloperidol (0.3 mg/kg), compound 13 (28, 42, and
70 mg/kg), or clozapine (30 mg/kg). Catalepsy severity was as-
sessed at time points (15, 30, 45, 60, and 90 min) post-injection,
by scoring how long the rat maintained both forepaws motionless
on a horizontal metal bar (1.1 cm in diameter, 10 cm above the
bench top in a box) up to a maximum of 120 s. This was repeated
two more times and the average (n = 3 tries) seconds recorded for
each rat. The mean of all the average seconds for one dose for one
time point (n = 5–8 rats) was divided by 5 and a mean catalepsy
score assigned and plotted in Figure 4 with a maximum possible
score of 24.
Acknowledgments
13. Matsui-Sakata, A.; Ohtani, H.; Sawada, Y. Drug Metab. Pharmacokinet. 2005, 20,
368.
We gratefully acknowledge the financial support of the National
Institute of General Medical Studies (NIGMS) for MBRS Grant No.
GM 08111, NIMH Psychoactive Drug Screening Program, RCMI
Grant No. G12 RR 03020 from NCRR, and a Title III Grant to Florida
A&M University. The authors also acknowledge the original bind-
ing studies conducted by A. W. Schmidt at Pfizer Global Research.
This work was supported in part by the Pharmaceutical Research
Center NIH/NCRR 1 C06-RR12512-01 Grant.
14. (a) Sanberg, P. R.; Bunsey, M. D.; Giordano, M.; Norman, A. B. Behav. Neurosci.
1988, 102, 748; (b) Crocker, A. D.; Hemsley, K. M. Prog. Neuropsychophamachol.
Biol. Psychiatry 2001, 25, 573; (c) Hoffman, D. C.; Donovan, H.
Psychopharmacology 1995, 120, 128.
15. Cignarella, G.; Giangiacomo, N.; Emilio, O. J. Org. Chem. 1961, 26, 2747.
16. Thompson, P. E.; Zeigler, J. B.; McCall, J. W. J. Med. Chem. 1974, 17,
481.
17. Yevich, J. P.; New, J. S.; Lobeck, W. G.; Dextraze, P.; Bernstein, E.; Taylor, D. P.;
Yocca, F. D.; Eison, M. S.; Temple, D. L., Jr. J. Med. Chem. 1992, 35, 4516.
18. (a) Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K. Nature 1976, 261, 717; (b)
Seeman, P.; Chau-Wong, M.; Tedesco, J.; Wong, K. Proc. Natl. Acad. Sci. U.S.A.
1975, 72, 4376; (c) Seeman, P.; Corbett, R.; Van Tol, H. H. M.
Neuropsychopharmacology 1997, 16, 93.
References and notes
19. (a) Bardin, L.; Auclair, A.; Kleven, M. S.; Prinssen, E. P.; Koek, W.; Newman-
Tancredi, A.; Depoortère, R. Behav. Pharmacol. 2007, 18, 103; (b) Cuisiat, S.;
Bourdiol, N.; Lacharme, V.; Newman-Tancredi, A.; Colpaert, F.; Vacher, B.J. Med.
Chem. 2007, 50, 865.
20. (a) Meltzer, H. Y.; Matsubara, S.; Lee, J.-C. J. Pharmacol. Exp. Ther. 1989, 251,
238; (b) Rasmussen, K.; Aghajanian, G. K. Neuropsychopharmacology 1988, 1,
101.
1. Crilly, J. Hist. Psychiatry 2007, 18, 39.
2. (a) Peabody, C. A.; Brody, D.; Warner, M. D. Biol. Psychiatry 1987, 22, 111; (b)
Riddle, M. A.; Hardin, M. T.; Towbin, K. E.; Leckman, J. F.; Cohen, D. J. Arch. Gen.
Psychiatry 1987, 44, 98; (c) Chirita, V.; Boisteanu, P.; Pirozynski, T. Rev. Med.
Chir. Soc. Med. Nat. Iasi. 1987, 91, 53; (d) Munyon, W. H.; Salo, R.; Briones, D. F.
Psychopharmacology (Berlin) 1987, 91, 182; (e) Petty, L. K.; Spar, C. J. Am. J.
Psychiatry 1980, 137, 745; (f) Gerlach, J.; Simmelsgaard, H. Psychopharmacology
(Berlin) 1978, 59, 105.
21. Meltzer, H. Y.; Li, Z.; Kaneda, Y.; Ichikawa, J. Prog. Neuropsychopharmacol. Biol.
Psychiatry 2003, 27, 1159.
22. (a) Kroeze, W. K.; Hufeisen, S. J.; Popadak, B. A.; Renock, S. M.; Steinberg, S.;
Ernsberger, P.; Jayathilake, K.; Meltzer, H. Y.; Roth, B. L.
Neuropsychopharmacology 2003, 28, 519; (b) Matsui-Sakata, A.; Ohtani, H.;
Sawada, Y. Drug Metab. Pharmacokinet. 2005, 20, 368.
23. (a) Setola, V.; Dukat, M.; Glennon, R. A.; Roth, B. L. Mol. Pharmacol. 2005, 68, 20;
(b) Rothman, R. B.; Baumann, M. H.; Savage, J. E.; Rauser, L.; McBride, A.;
Hufeisen, S. J.; Roth, B. L. Circulation 2000, 102, 2836; (c) http://
3. Ablordeppey, S. Y.; Borne, R. F. Pharmacol. Biochem. Behav. 1993, 46, 739.
4. (a) Subramanyam, B.; Rollema, H.; Woolf, T.; Castagnoli, N., Jr. Biochem. Biophys.
Res. Commun. 1990, 166, 238; (b) Subramanyam, B.; Pond, S. M.; Eyles, D. W.;
Whiteford, H. A.; Fouda, H. G.; Castagnoli, N., Jr. Biochem. Biophys. Res. Commun.
1991, 181, 573; (c) Subramanyam, B.; Woolf, T.; Castagnoli, N., Jr. Chem. Res.
Toxicol. 1991, 4, 123.
5. (a) Fang, J.; Gorrod, J. W. Toxicol. Lett. 1991, 59, 117; (b) Eyles, D. W.; McLennan,
H. R.; Jones, A.; McGrath, J. J.; Stedman, T. J.; Pond, S. M. Clin. Pharmacol. Ther.
1994, 56, 512; (c) Eyles, D. W.; Avent, K. M.; Stedman, T. J.; Pond, S. M. Life Sci.
1997, 60, 529; (d) Fang, J.; Zuo, D.; Yu, P. H. Psychopharmacology 1995, 121, 373;
(e) Rollema, H.; Skolnik, M.; D’Engelbronner, J.; Igarashi, K.; Usuki, E.;
Castagnoli, N., Jr. J. Pharmacol. Exp. Ther. 1994, 268, 380.
25. Michaels, R. J.; Zaugg, H. E. J. Org. Chem. 1960, 25, 637.
26. (a) Shapiro, D. A.; Renock, S.; Arrington, E.; Chiodo, L. A.; Liu, L. X.; Sibley, D. R.;
Roth, B. L.; Mailman, R. Neuropsychopharmacology 2003, 28, 1400; (b) See
references in Ref. 25.
6. (a) Ablordeppey, S. Y.; Lyles-Eggleston, M.; Bricker, B.; Zhang, W.; Zhu, X. Y.;
27. (a) Needham, P. L.; Atkinson, J.; Skill, M. J.; Heal, D. J. Psychopharmacol. Bull.
1996, 32, 123; (b) Protais, P.; Costentin, J.; Schwartz, J. C. Psychopharmacology
1976, 50, 1.
28. (a) Hoffman, D. C.; Donovan, H. Psychopharmacology (Berlin) 1995, 120, 128; (b)
Hoffman, D. C.; Donovan, H. Psychopharmacology (Berlin) 1994, 115, 447.
Goodman, C.; Roth, B. L.
Ablordeppey, S. Y.; Borne, R. F. Med. Chem. Res. 1993, 3, 459.
7. Lyles-Eggleston, M.; Altundas, R.; Xia, J.; Sikazwe, D. M. N.; Fan, P.; Yang, Q.; Li,
S.; Zhang, W.; Zhu, X.; Schmidt, A. W.; Vanase-Frawley, M.; Shrihkande, A.;
Villalobos, A.; Ablordeppey, S. Y. J. Med. Chem. 2004, 47, 497.
Bioorg. Med. Chem. Lett. 2006, 16, 3219; (b)